E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty
Koon Hou Mak,Mark J. Eisenberg,David S. Eccleston,Kimberly Brown,Stephen G. Ellis,Eric J. Topol +5 more
TL;DR: Although reusing coronary angioplasty catheters may reduce total in-hospital costs, even a modest increase in complications requiring urgent revascularization may offset any potential savings.
Journal ArticleDOI
Abrupt closure: The CAVEAT I experience
David R. Holmes,John B. Simpson,John B. Simpson,Lisa G. Berdan,Lisa G. Berdan,Ronald S. Gottlieb,Ronald S. Gottlieb,Ferdinand Leya,Ferdinand Leya,Gordon Keeler,Gordon Keeler,Robert M. Califf,Robert M. Califf,Eric J. Topol,Eric J. Topol +14 more
TL;DR: Although abrupt closure is more common with directional atherectomy than angioplasty, the sequelae are similar and abrupt closure remains the principal determinant of adverse outcome after percutaneous procedures for the treatment of coronary artery disease.
Journal ArticleDOI
ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
Fernando A. Cura,Marco Roffi,Narcis Pasca,Katherine E. Wolski,A. Michael Lincoff,Eric J. Topol,Michael S. Lauer +6 more
TL;DR: ST-segment resolution at 60 minutes was no different in patients treated with full-dose reteplase from those treated with a combination of abciximab and rete Plase, irrespective of treatment.
Journal ArticleDOI
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
TL;DR: The trial aims to evaluate improved anticoagulation with bivalirudin and preprocedural oral antiplatelet protection and the use of ad hoc abciximab as a basis for a practical, acceptable antithrombotic, antiplatelets strategy to improve outcomes in percutaneous coronary revascularization.
Journal ArticleDOI
The Lost Decade of Nesiritide
TL;DR: In this issue of the Journal, O'Connor and colleagues report the results of a large, randomized, placebo-controlled trial on the deficient clinical development of certain pharmaceutical agents.